AbbVie Inc. Files 8-K: Operations & Financials Update
Ticker: ABBV · Form: 8-K · Filed: Apr 29, 2026 · CIK: 0001551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Apr 29, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k, operations
Related Tickers: ABBV
TL;DR
ABBV dropped an 8-K on 4/29 - check the financials.
AI Summary
AbbVie Inc. filed an 8-K report on April 29, 2026, detailing its results of operations and financial condition. The filing includes financial statements and exhibits, with the primary document being the 8-K itself in iXBRL format.
Why It Matters
This filing provides investors with crucial, up-to-date information on AbbVie's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing reporting financial results and exhibits, not indicating any unusual or negative events.
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 8-K report
- 0001551152 (company) — CIK number for AbbVie Inc.
- 2026-04-29 (date) — Filing date and period of report
FAQ
What specific financial results are detailed in this 8-K filing?
The filing is an 8-K report for April 29, 2026, under Item 2.02, which covers Results of Operations and Financial Condition, but the specific figures are not detailed in the provided text.
What is the filing date of this 8-K report?
The filing date of this 8-K report for AbbVie Inc. is April 29, 2026.
What are the main items reported in this 8-K filing?
The main items reported are Item 2.02: Results of Operations and Financial Condition, and Item 9.01: Financial Statements and Exhibits.
What is the CIK number for AbbVie Inc. mentioned in the filing?
The CIK number for AbbVie Inc. is 0001551152.
Where is AbbVie Inc.'s principal executive office located?
AbbVie Inc.'s principal executive office is located at 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2026 regarding AbbVie Inc. (ABBV).